Anthony del Priore, MD
Internal Medicine · Chicago, ILNPI 1275888216
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 409 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 19.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,829, 2.6 times the $702 reported in 2019. Among internal medicine clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 409 payments — averaging $21.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Novo Nordisk$1K
- Lilly USA, LLC$1K
- Pfizer$530
- Bayer$513
- Novartis$480
- plus $4K from 32 others
Across 7 payments — averaging $1204.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$8K
What the payments were for
- Food & beverage$8,784100%
- Education$290%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 70 | $1,680 |
| Novo Nordisk | 67 | $1,060 |
| Lilly USA, LLC | 52 | $1,011 |
| Pfizer | 23 | $530 |
| Bayer | 20 | $513 |
| Novartis | 24 | $480 |
| Abbott | 17 | $429 |
| Amgen | 18 | $356 |
| AbbVie(2 entities) | 13 | $253 |
| Exact Sciences | 9 | $214 |
| GSK | 10 | $199 |
| Johnson & Johnson | 7 | $180 |
| Neurocrine Biosciences, Inc. | 2 | $166 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $155 |
| Otsuka America Pharmaceutical, Inc. | 7 | $154 |
| Sanofi-aventis U.S. LLC | 7 | $137 |
| Angiodynamics, Inc. | 1 | $134 |
| Teva Pharmaceuticals USA, Inc. | 5 | $133 |
| Sumitomo Pharma America, Inc. | 7 | $126 |
| Merck | 6 | $122 |
| Boehringer Ingelheim | 6 | $117 |
| E.r. Squibb & Sons, L.L.C. | 5 | $99 |
| Vivus LLC | 4 | $85 |
| Astellas Pharma US Inc | 3 | $61 |
| Alpha Cognition USA, Inc. | 1 | $55 |
| Medtronic | 1 | $47 |
| Boston Scientific | 2 | $46 |
| Scpharmaceuticals Inc. | 2 | $43 |
| Amphastar Pharmaceuticals, Inc. | 2 | $43 |
| Melinta Therapeutics, LLC | 1 | $25 |
| Dexcom, Inc. | 1 | $25 |
| Amarin Pharma, Inc. | 1 | $21 |
| CMP Pharma, Inc. | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Galderma Laboratories, L.p. | 1 | $20 |
| Scilex Pharmaceuticals Inc. | 1 | $20 |
| Clarus Therapeutics Inc. | 2 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,814 in reported general payments places this provider in the 95th percentile of 5,182 internal medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 815 | $302,305 |
| OzempicSemaglutide | 81 | $109,466 |
| XareltoRivaroxaban | 226 | $81,355 |
| FarxigaDapagliflozin Propanediol | 99 | $65,787 |
| MounjaroTirzepatide | 30 | $44,559 |
| JardianceEmpagliflozin | 98 | $44,309 |
| EntrestoSacubitril/Valsartan | 72 | $43,086 |
| TrulicityDulaglutide | 33 | $38,477 |
| JanuviaSitagliptin Phosphate | 54 | $32,606 |
| KerendiaFinerenone | 25 | $32,447 |
| Sevelamer Carbonate | 62 | $25,445 |
| MyrbetriqMirabegron | 55 | $23,541 |
| Atorvastatin Calcium | 1,480 | $22,108 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $21,033 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $19,551 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $530 | $302,305815 claims |
| Novo NordiskOzempic | $1,060 | $109,46681 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,680 | $85,338114 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,011 | $83,03563 claims |
| Johnson & JohnsonXarelto | $180 | $81,355226 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta | $199 | $49,47785 claims |
| Boehringer IngelheimJardiance | $117 | $44,30998 claims |
| NovartisEntresto | $480 | $43,08672 claims |
| MerckJanuvia | $122 | $32,60654 claims |
| BayerKerendia | $513 | $32,44725 claims |
| Astellas Pharma US IncMyrbetriq | $61 | $23,54155 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $126 | $16,53333 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in Chicago
- Merle DiamondChicago$1.1M
- Robert KushnerChicago$516K
- Romeo UrsuaChicago$420K
- Peter O DonnellChicago$318K
- George UrbanChicago$258K
- Kristen PallokChicago$256K
- George NissanChicago$252K
- Luke LaffinChicago$162K
- Daniel CatenacciChicago$161K
- Hiren ShahChicago$144K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.